Clinical Trial Update: Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is ongoing to assess the response to solriamfetol for treating major depressive disorder with excessive daytime sleepiness.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Solriamfetol (solriamfetol)

Snippet

Sponsor: Axsome Therapeutics, Inc. | Conditions: Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms | Phase 3 | Status: RECRUITING